Draft:Shalabh Gupta

Shalabh Gupta, MD is an Indian-American physician and entrepreneur. He is the founder and CEO of Unicycive Therapeutics, a biopharmaceutical company.

Life and career
Gupta earned his MD from Jawaharlal Institute of Postgraduate Medical Education & Research in India. In 1999, he graduated with a Master's in Public Administration (MPA) in Health Care Finance and Management from New York University.

From 2004 to 2008, Gupta served as an attending physician at New York University (NYU) Medical Center and held a clinical faculty position at the NYU School of Medicine.

During the early part of his career he served in different roles. Gupta worked as a medical advisor to Synageva and a commercial strategist at Genentech. Additionally, he also worked as an equity researcher covering US pharmaceutical companies at UBS Investment Bank, and also worked as an equity researcher covering biotechnology companies at Rodman & Renshaw.

BioCycive
In 2011, Gupta founded BioCycive, a biotechnology company focused on oncology.

Globavir
In 2013, Gupta founded Globavir, a therapeutics and diagnostics company.

Unicycive Therapeutics
In August 2016, Gupta founded Unicycive Therapeutics, a biopharmaceutical company involved in the research and development of treatment for kidney diseases.

Since 2020, Gupta serves as an advisor to the UCSF Innovation Center. He previously served on the Beall Center for Innovation and Entrepreneurship board of directors at the Paul Merage School of Business, University of California Irvine.

Gupta serves as an advisor to the UCSF Innovation Center and has been an advisor to SPARK at Stanford University School of Medicine since 2012.